List view / Grid view
The in vivo, one-time gene editing therapy has potential to…
The in vivo, one-time gene editing therapy has potential to transform outcomes for alpha-1 antitrypsin deficiency (AATD).
European approval of Sanofi and Regeneron’s monoclonal antibody provides eligible…
European approval of Sanofi and Regeneron’s monoclonal antibody provides eligible urticaria patients with a new first-line targeted treatment option.
The US approval could improve outcomes for eligible patients with…
The US approval could improve outcomes for eligible patients with previously limited options for managing the inflammatory skin condition.
Approval of the first treatment for patients one year old…
Approval of the first treatment for patients one year old and over with eosinophilic esophagitis (EoE) was based on trial data showing a greater proportion of children given Dupixent achieved histological remission compared to placebo.
Phase III trial data shows Dupixent® (dupilumab) has the potential…
Phase III trial data shows Dupixent® (dupilumab) has the potential to improve signs of eosinophilic oesophagitis (EoE) and support healthy weight gain in children with the condition.
Dupixent is the first biologic medicine to significantly reduce signs…
Dupixent is the first biologic medicine to significantly reduce signs and symptoms of atopic dermatitis in children as young as six months.
Phase III data shows treatment with REGEN-COV™ (casirivimab and imdevimab)…
Phase III data shows treatment with REGEN-COV™ (casirivimab and imdevimab) significantly reduces the risk of high-risk COVID-19 infected outpatients being hospitalised or dying.
In vitro neutralisation assays show REGEN-COV and AZD7442 are effective…
In vitro neutralisation assays show REGEN-COV and AZD7442 are effective against the new SARS-CoV-2 variants, while other antibody therapies, including Eli Lilly’s bamlanivimab, were not.
Interim data from the Phase III trial evaluating REGEN-COV™ as…
Interim data from the Phase III trial evaluating REGEN-COV™ as a passive vaccine to prevent COVID-19 finds it reduces overall infection rate, viral load and length of infection.
The EC has approved an extension of marketing authorisation for…
The EC has approved an extension of marketing authorisation for Regeneron and Sanofi's Dupixent (dupilumab) for children aged six to 11 with severe atopic dermatitis.
In combination with inhaled corticosteroids, the monoclonal antibody Dupixent improved…
In combination with inhaled corticosteroids, the monoclonal antibody Dupixent improved lung function and reduced the rate of severe asthma attacks.
REGN-COV2 will be evaluated alongside standard-of-care in a Phase III…
REGN-COV2 will be evaluated alongside standard-of-care in a Phase III study as part of the COVID-19 RECOVERY trial.
Simultaneous Phase III trials evaluating Regeneron’s REGN-COV2 antibody as both…
Simultaneous Phase III trials evaluating Regeneron’s REGN-COV2 antibody as both a prophylactic and a treatment have begun in US and some South American locations.
A Phase II/III trial to study Kevzara (sarilumab) as a…
A Phase II/III trial to study Kevzara (sarilumab) as a method to reduce the inflammatory response in the lungs of COVID-19 patients has begun outside of the US.
Led by Sanofi and Regeneron, clinical trials to examine Kevzara…
Led by Sanofi and Regeneron, clinical trials to examine Kevzara (sarilumab) as an effective COVID-19 treatment will begin in the US.
